Table 3.
Model 2. Association Between Plasma Adiponectin Levels and Neuroimaging and Cognitive Outcomes by Sex and Elevated (PiB-PET SUVR≥1.4) Amyloid Level
| Men with Elevated Amyloid | Women with Elevated Amyloid | |||
|---|---|---|---|---|
| B (95% CI) | P value | B (95% CI) | P value | |
| Neuroimaging outcomes | ||||
| HVa,* cm3 | −0.279 (−0.836, 0.278) | .324 | −0.723 (−1.43, −0.014) | 0.046 |
| AD signature thickness, mm | −0.013 (−0.150, 0.124) | .852 | 0.100 (−0.067, 0.266) | 0.238 |
| FDG PET, SUVR | −0.098 (−0.216, 0.019) | .101 | −0.054 (−0.186, 0.079) | 0.418 |
| Cognitive outcomes | ||||
| Memory domain, z-score | 0.020 (−0.739, 0.780) | .958 | −1.40 (−2.38, −0.422) | 0.005 |
| Language domain, z-score | −0.173 (−0.784, 0.438) | .577 | −1.03 (−1.82, −0.244) | 0.011 |
| Attention domain, z-score | 0.347 (−0.222, 0.915) | .231 | −0.654 (−1.45, 0.139) | 0.105 |
| Visual-spatial domain, z-score | −0.101 (−0.689, 0.488) | .735 | −0.196 (−1.03, 0.640) | 0.644 |
| Global cognition, z-score | 0.048 (−0.546, 0.642) | .873 | −1.07 (−1.85, −0.288) | 0.008 |
| Men with Lower Amyloid Levels | Women with Lower Amyloid Levels | |||
|---|---|---|---|---|
| B (95% CI) | P value | B (95% CI) | P value | |
| Neuroimaging outcomes | ||||
| HVa,* cm3 | 0.080 (−0.537, 0.696) | .799 | −0.458 (−1.63, 0.716) | .438 |
| AD signature thickness, mm | 0.010 (−0.017, 0.038) | .467 | 0.022 (−0.030, 0.073) | .403 |
| FDG PET, SUVR | −0.078 (−0.209, 0.054) | .244 | 0.026 (−0.209, 0.261) | .826 |
| Cognitive outcomes | ||||
| Memory domain, z-score | −0.028 (−0.828, 0.772) | .945 | 0.639 (−0.981, 2.26) | .433 |
| Language domain, z-score | 0.194 (−0.492, 0.880) | .576 | −0.635 (−1.73, 0.462) | .251 |
| Attention domain, z-score | −0.256 (−0.902, 0.390) | .434 | −0.378 (−1.61, 0.857) | .542 |
| Visual-spatial domain, z-score | −0.349 (−1.09, 0.389) | .351 | −0.621 (−2.04, 0.795) | .383 |
| Global cognition, z-score | −0.079 (−0.783, 0.624) | .824 | −0.351 (−1.68, 0.977) | .598 |
Models were adjusted for age, years of education, waist-to-hip ratio, current diabetes and hypertension, and APOE ε4 status. A+ Men: neuroimaging outcomes, n=182; memory, n=181; language, n=176; attention, n=171; visual-spatial, n=171; global, n=166. A+ Women: MRI, n=133; memory, n=132; language, n=128; attention, n=130; visual-spatial, n=128; global, n=126. A- Men: HVa, n=129; FDG PET, n=131; cortical thickness, n=128; memory, n=131; language, n=130; attention, n=127; visual-spatial, n=129; global, n=127. A- Women: neuroimaging outcomes, n=66; memory, n=66; language and visual-spatial, n=63; attention, n=62; global, n=62.
HVa adjusted for total intracranial volume.